At the Goldman Sachs 47th Annual Global Healthcare Conference held on June 8, 2026, Pacira BioSciences, Inc. (PCRX) CEO Frank Lee provided insights into the company's operations and future direction. Pacira is recognized for its leadership in non-opioid pain management therapies, boasting three products in its portfolio and a developing pipeline. Lee, who has been with the company for over two years, discussed a significant organizational reset that took place in 2024, which has positioned the company for growth. He emphasized the 5x30 strategy for value creation, which outlines five key initiatives aimed at enhancing the company's market presence and operational efficiency. As the company looks towards the second half of the year and beyond, Lee highlighted the importance of aligning their strategic priorities with market needs and advancing their product offerings to address pain management without the reliance on opioids. This approach aligns with current healthcare trends emphasizing safer pain management alternatives.